Antibodies Directed to HER-3 and Uses Thereof
AssigneesU3 Pharma GmbH, Amgen Inc.
InventorsMike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges, Larry L. Green
Life of this patent
Estimating the term…
Abstract
The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
Claims11
1-52. (canceled)
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises a heavy chain amino acid sequence that comprises a CDRH1 selected from the group consisting of SEQ ID NOs:236, 251, 252, and 256, a CDRH2 selected from the group consisting of SEQ ID NOs:258, 278, 280, and 282, and a CDRH3 selected from the group consisting of SEQ ID NOs:283, 285, 309, 313, and 315, and a light chain amino acid sequence that comprises a CDRL1 selected from the group consisting of SEQ ID NOs:320, 334, 337, and 340, a CDRL2 selected from the group consisting of SEQ ID NOs:
- 343, 356, 351, and 344, and a CDRL3 selected from the group consisting of SEQ ID NOs:360, 381, 385, and 387.
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs:
- 42, 70, 92, and 96.
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises a light chain amino acid sequence selected from the group consisting of SEQ ID NOs:
- 44, 56, 72, 94, and 98.
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs:
- 42, 54, 70, 92, and 96;
- and a light chain amino acid sequence selected from the group consisting of SEQ ID NOs:
- 44, 56, 72, 94, and 98.
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises the heavy chain amino acid sequence of SEQ ID NO:42 and the light chain amino acid sequence of SEQ ID NO:44.
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises the heavy chain amino acid sequence of SEQ ID NO:54 and the light chain amino acid sequence of SEQ ID NO:56.
A method for treating or preventing a disease associated with HER-3 in a patient, comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising as an active ingredient an isolated binding protein that binds to HER-3, wherein said binding protein comprises the heavy chain amino acid sequence of SEQ ID NO:70 and the light chain amino acid sequence of SEQ ID NO:72.
Dependencies are inferred from the claim text.